Seminars in Oncology
Volume 29, Issue 3 , Pages 258-263 , June 2002

Clinical translation of gene expression profiling in lymphomas and leukemias

References 

  1. Harris NL, Jaffe ES, Diebold J, et al.  Lymphoma classification—From controversy to consensus: The R.E.A.L. and WHO classification of lymphoid neoplasms. Ann Oncol. 2000;11:3–10
  2. Harris NL, Jaffe ES, Stein H, et al.  A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392
  3. In:  Jaffe ES,  Harris NL,  Stein H, et al. editor. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001;
  4. Staudt LM, Brown PO. Genomic views of the immune system. Ann Rev Immunol. 2000;18:829–859
  5. Alizadeh AA, Eisen MB, Davis RE, et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  6. Hamblin TJ, Davis Z, Gardiner A, et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854
  7. Damle RN, Wasil T, Fais F, et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847
  8. Rosenwald A, Alizadeh AA, Widhopf GF, et al.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639–1647
  9. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol. 2001;13:325–334
  10. Fisher RI. Diffuse large-cell lymphoma. Ann Oncol. 2000;11:29–33
  11. Engelhard M, Brittinger G, Huhn D, et al.  Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: Distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood. 1997;89:2291–2297
  12. Brittinger G, Bartels H, Common H, et al.  Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas: Results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol. 1984;2:269–306
  13. Melnyk A, Rodriguez A, Pugh WC, et al.  Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood. 1997;89:4514–4520
  14. Salar A, Fernandez de Sevilla A, Romagosa V, et al.  Diffuse large B-cell lymphoma: Is morphologic subdivision useful in clinical management?. Eur J Haematol. 1998;60:202–208
  15. The International Non-Hodgkin's Lymphoma Prognostic Factors Project . A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987–994
  16. Shaffer AL, Rosenwald A, Hurt EM, et al.  Signatures of the immune response. Immunity. 2001;15:375–385
  17. Lossos IS, Alizadeh AA, Eisen MB, et al.  Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA. 2000;97:10209–10213
  18. Caligaris-Cappio F. Biology of chronic lymphocytic leukemia. Rev Clin Exp Hematol. 2000;4:5–21
  19. Golub TR, Slonim DK, Tamayo P, et al.  Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–537
  20. Davis RE, Brown KD, Siebenlist U, et al.  Constitutive NF-κB activity is required for survival of activated B-like diffuse large B-cell lymphoma cells. J Exp Med. 2001;194:1861–1874
  21. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107:241–246
  22. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: A new strategy in cancer treatment. Invest New Drugs. 2000;18:109–121

☆ Address reprint requests to Louis M. Staudt, MD, PhD, Metabolism Branch, NCI, Bldg 10, Room 4N114, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

☆☆ This is a US government work. There are no restrictions on its use.

PII: S0093-7754(02)50181-0

doi: 10.1053/sonc.2002.32901

Seminars in Oncology
Volume 29, Issue 3 , Pages 258-263 , June 2002

Article Tools

* Image Usage & Resolution